**Author details**

Christian Focan\*, Anne-Catherine Davin, Maryam Bourhaba and Marie-Pascale Graas CHC-Liège, ESMO Integrated Center for Oncology and Palliative Care, Oncology Department, Liege, Belgium

\*Address all correspondence to: christian.focan@chc.be

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**89**

*Integration of Chronobiological Concepts for NSCLC Management*

[10] Davis S, Minck DK. Circadian disruption shift work and the risk of cancer: A summary of the evidence and studies in Seattle. Cancer Causes &

[11] Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. Journal of Biological Rhythms.

Control. 2006;**17**(4):539-545

[12] Yang X, Wood PA, Ansell C, Hrushesky WJ. Circadian timedependent tumor suppressor function of period genes. Integrative Cancer Therapies. 2009;**8**(4):309-316

[13] Hua H, Wang Y, Wan C, et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer

[14] Focan C. Chronobiological concepts underlying the chronotherapy of human lung cancer. Chronobiology International. 2002;**19**(1):253-273

[15] Hashimoto N, Endoh D, Kuwabara M, et al. Induction of lung tumors in C3H strain mice after single or fractionated irradiation with X-rays. The Journal of Veterinary Medical Science. 1994;**56**(3):493-498

[16] Filipski Z, Subramabian P, Carriere J, et al. Circadian disruption accelerates liver carcinogenesis in mice. Mutation Research. 2009;**680**(1-2):95-105

[17] Gery S, Komatsu N, Kawamata N, et al. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clinical Cancer Research.

[18] Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. Journal of the National Cancer Institute.

2007;**13**(5):1399-1404

2000;**92**(12):994-1000

Science. 2006;**97**(7):589-596

2007;**22**(4):291-298

*DOI: http://dx.doi.org/10.5772/intechopen.85710*

[1] Focan C. Circadian rhythms and cancer chemotherapy. Pharmacology &

[2] Focan C. Marker rhythms for cancer chronotherapy. From laboratory animals to human beings. In Vivo.

Therapeutics. 1995;**67**(1):1-52

[3] Levi F, Focan C, Karaboué A, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced Drug Delivery

Reviews. 2007;**59**(9):1015-1035

R, Rand DA, Lévi FA. Systems chronotherapeutics. Pharmacological Reviews. 2017;**69**:161-199. DOI: 10.1124/

[6] Gery S, Koeffler HP. The role of circadian regulation in cancer. Cold Spring Harbor Symposia on Quantitative Biology. 2007;**72**:459-464

[7] Kramer A, Yang FC, Snodgrass P, et al. Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signalling. Novartis Foundation

[8] Vadigepalli R, Hao H, Miller GM, Liu H, Schwaber HS. Epidermal growth factor receptor-induced circadian time-dependent gene relation in suprachiasmatic nucleus. Neuroreport.

[9] Gery S, Komatsu N, Baldiyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Molecular Cell.

Symposium. 2003;**253**:250-262

2008;**18**:1437-1441

2006;**22**:375-382

pr.116.013441

[4] Innominato PF, Roche VP, Palesh OG, et al. The circadian timing system in clinical oncology. Annals of Medicine. 2014;**46**(4):191-207. DOI: 10.3109/07853890.2014.916990

[5] Ballesta A, Innominato PF, Dallmann

**References**

1995;**9**:283-298

*Integration of Chronobiological Concepts for NSCLC Management DOI: http://dx.doi.org/10.5772/intechopen.85710*
